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Abstract
Background: Kidney Renal Clear Cell Carcinoma (KIRC) is one of fatal genitourinary diseases and accounts for most
malignant kidney tumours. KIRC has been shown resistance to radiotherapy and chemotherapy. Like many types of
cancers, there is no curative treatment for metastatic KIRC. Using advanced sequencing technologies, The Cancer
Genome Atlas (TCGA) project of NIH/NCI-NHGRI has produced large-scale sequencing data, which provide
unprecedented opportunities to reveal new molecular mechanisms of cancer. We combined differentially
expressed genes, pathways and network analyses to gain new insights into the underlying molecular mechanisms
of the disease development.
Results: Followed by the experimental design for obtaining significant genes and pathways, comprehensive
analysis of 537 KIRC patients’ sequencing data provided by TCGA was performed. Differentially expressed genes
were obtained from the RNA-Seq data. Pathway and network analyses were performed. We identified 186
differentially expressed genes with significant p-value and large fold changes (P < 0.01, |log(FC)| > 5). The study not
only confirmed a number of identified differentially expressed genes in literature reports, but also provided new
findings. We performed hierarchical clustering analysis utilizing the whole genome-wide gene expressions and
differentially expressed genes that were identified in this study. We revealed distinct groups of differentially
expressed genes that can aid to the identification of subtypes of the cancer. The hierarchical clustering analysis
based on gene expression profile and differentially expressed genes suggested four subtypes of the cancer. We
found enriched distinct Gene Ontology (GO) terms associated with these groups of genes. Based on these findings,
we built a support vector machine based supervised-learning classifier to predict unknown samples, and the
classifier achieved high accuracy and robust classification results. In addition, we identified a number of pathways
(P < 0.04) that were significantly influenced by the disease. We found that some of the identified pathways have
been implicated in cancers from literatures, while others have not been reported in the cancer before. The network
analysis leads to the identification of significantly disrupted pathways and associated genes involved in the disease
development. Furthermore, this study can provide a viable alternative in identifying effective drug targets.
Conclusions: Our study identified a set of differentially expressed genes and pathways in kidney renal clear cell
carcinoma, and represents a comprehensive computational approach to analysis large-scale next-generation
sequencing data. The pathway and network analyses suggested that information from distinctly expressed genes
can be utilized in the identification of aberrant upstream regulators. Identification of distinctly expressed genes and
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altered pathways are important in effective biomarker identification for early cancer diagnosis and treatment
planning. Combining differentially expressed genes with pathway and network analyses using intelligent
computational approaches provide an unprecedented opportunity to identify upstream disease causal genes and
effective drug targets.
Background
Cancer is not only complex, in that many genetic varia-
tions can contribute to malignant transformation, but
also wildly heterogeneous, in that genetic mechanisms
can vary between patients of same pathological type.
Kidney Renal Clear Cell Carcinoma (KIRC) is the eighth
most common cancer and is known to be the most lethal
of all the genitourinary tumours with an estimation of
approximately 65,000 new cases and approximately
13,000 deaths annually in United States [1]. This disease
is known resistant to radiotherapy and chemotherapy [2],
and there are very few cases that have been reported to
respond immunotherapy [3]. If KIRC can be detected in
very early stages, it is potentially curable by surgical
resection, while adjuvant therapies have not been proven
beneficial. The recurrence rate is not very high, although
still considered not uncommon. Nevertheless, there is no
curative treatment for late stage KIRC. The 2-year survi-
val rate of patients with metastatic KIRC is less than 20%
[4,5]. Therefore, further investigations of the genomic
alterations and underlying molecular mechanisms are
essential for early diagnosis and treatment. As cancer is a
consequence of the accumulation of genetic alterations
and dysregulation of pathways, identification of differen-
tially expressed genes and pathways is important. We
aimed to develop integrative approaches to identify dif-
ferentially expressed genes and pathways in combination
with gene network analysis for finding effective early
cancer biomarkers and drug targets.
In this study, we designed computational approaches to
identify differentially expressed genes from the RNA-seq
data provided by the TCGA data portal. We further per-
formed Gene Ontology (GO) analysis and categorized
expression patterns. Categorization of differentially
expressed genes and expression patterns suggested dis-
tinct disease subtypes that are associated with distinct
biological processes. Many studies have indicated that
same type of cancer can have different subtypes with dif-
ferent genetic mechanisms and treatment responses.
Bannon et.al. discovered two distinct KIRC subtypes
using gene microarray expression data [6], whereas four
stable subtypes of KIRC were detected using both mRNA
and miRNA expression data sets [7]. Despite of discov-
eries of differentially expressed genes and genetic muta-
tions, the knowledge of biological pathways involved in
the disease is limited. To facilitate the effective biomarker
identification, we therefore further analysed pathways
and gene networks related to the differentially expressed
genes.
KEGG (Kyoto Encyclopaedia of Genes and Genomes,
http://www.genome.jp/kegg/) pathway analysis revealed
that differentially expressed genes are significantly
enriched in a number of biological pathways that are
known in cancer, as well as previously unreported path-
ways. This study provided new insights into the regulatory
mechanisms of KIRC through comprehensive differential
gene expression, pathway and network analyses.
Results
Differentially expressed genes in KIRC
Analysis of 186 differentially expressed genes was per-
formed using RNA-seq data of 537 KIRC patients from the
TCGA data portal, including both matched and
unmatched samples. Matched samples have sequencing
data from both normal kidney and kidney cancer tissues in
the same KIRC patients, whereas unmatched samples only
have sequencing data from either disease or no disease tis-
sues. TCGA data not only contain 68 matched KIRC
tumour and normal kidney tissue paired sequencing data,
but also provide 469 unpaired tumour and 4 normal kidney
tissue sequencing data. We applied multidimensional scal-
ing (MDS) on the 68 paired KIRC samples and found that
almost all tumour and normal samples were separated well
from each other (Figure 1). The MDS result suggested that
TCGA data quality was acceptable. We performed differ-
ential gene expression analysis using edgeR [8,9] package.
Using statistical P-values and fold changes (FC) as selection
criteria, we identified 186 differentially expressed genes
with P < 0.01, and |log(FC)| > 5 (additional file 1). These
differentially expressed genes not only confirmed some
previous research findings but also provided new findings.
For example, TNFAIP, a known tumour a-induced protein
that acts as a natural brake on inflammation [10], was up-
regulated in KIRC in the analysis. Another differentially
expressed gene, SLC6A3, which is implicated in lung and
breast cancer [11,12], has not yet been well known in
KIRC. Based on the expression levels of differentially
expressed genes, we performed hierarchical clustering ana-
lysis and revealed homogenous tumour and normal (no
cancer) clusters (Figure 2). Only one normal sample and
one tumour sample were mis-clustered, but both samples
came from the same patient (paired samples). This sug-
gested that they are more likely mislabelled rather outliers.
The expression levels of the differential genes showed
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distinct patterns between tumour and normal kidney tissue
samples. We clustered both overly expressed genes and
genes with diminished expression in tumour samples
(Figure 2). We performed GO (Gene Ontology) [13] analy-
sis on four groups of genes defined as over-expressed,
under-expressed, weakly over-expressed and weakly under-
expressed. Fisher exact test and Benjamini-Hochberg mul-
tiple testing corrections were performed to obtain signifi-
cance with GO terms. The significant GO terms associated
with each group are listed in Table 1. The over-expressed
genes are significantly associated with biological processes
of defence responses and responses to environmental sti-
mulus. The under-expressed genes are associated with
organismal physiological processes, system development
and organ development. Furthermore, we performed hier-
archical clustering of all samples including 469 unpaired
KIRC and 4 normal samples using the differentially
expressed genes detected from the matched samples. In
consistence with the results of the matched sample analysis,
we obtained two homogeneous clusters; only 4 including
the mis-labelled sample out of all 537 samples (Figure 3)
were mis-clustered, demonstrating that overall, the identi-
fied differentially expressed genes can effectively distinguish
KIRC from normal kidney tissue samples. Furthermore,
we have combined the pathway and network analyses
to enhance overall classification performance. From the
comprehensive analyses, the up-regulated genes were
strongly associated with cellular responses to the tumour
development, and the down-regulated genes implicated
compromises of kidney function as result of the cancer.
Kidney functional damages are common among cancer
patients. In addition to biological function association, the
distinct gene groups lead to the identification of subtypes of
KIRC.
Biological pathways associated with KIRC
We employed hypergeometric test to assess the differen-
tially expressed genes in KEGG [14] pathway analysis
to identify significant pathways involved in the cancer.
Significantly affected pathways in KIRC include taurine
and hypotaurine metabolism (Figure 4), neuroactive
ligand-receptor interaction, glycosaminoglycan biosynth-
esis - heparin sulphate, Peroxisome Proliferator-Acti-
vated Receptor (PPAR) signalling pathway (Figure 5),
and hepatitis C, gastric acid secretion pathway (Table 2).
Methylation of the genes in taurine and hypotaurine
metabolism has been associated with the worst prog-
nosis in renal cell carcinoma [15]. Hepatitis C pathway
has been implicated in kidney tumour [16-18]. Some of
those pathways are known related to cancer, for exam-
ple, PPAR signalling pathway has been shown related to
renal cell carcinoma [19]. In addition, Ingenuity (http://
www.ingenuity.com) pathway analysis revealed most sig-
nificant networks (P < 0.01), including network of mole-
cular transport, hereditary disorder, metabolic disease
(Figure 6), and network of renal and urological disease
(Figure 7), respectively. In the figures, nodes in red col-
our represent genes that are up-regulated, while notes
in green colour represent genes that are down-regulated
in the disease. Nodes circled in yellow colour represent
genes that have been known implicated in cancer. Inter-
estingly, most differentially expressed genes located at
the periphery of the networks are more likely down-
stream targets rather than regulators themselves. The
central node of molecular transport, hereditary disorder,
and metabolic disease network is NF-B (nuclear factor
kappa-light-chain-enhancer of activated B cells), which
is known active in kidney carcinoma and plays roles in
tumour development as well as therapeutic resistance
[20,21]. UBC (ubiquitin C), a gene associated with pro-
tein degradation, DNA repair and cell cycle regulation,
is located at the centre of the renal and urological dis-
ease network, and interconnects many other genes in
the network as a hub protein. UBC has been implicated
in breast cancer and contributes to cancer metastasis
[22]. In cancer studies, we often firstly identify differen-
tially expressed genes to help find the biomarkers for
tumour early detection, and then use the results to identify
upstream disease causal genes through further network
analysis. In this study, we combined the investigation of
differentially expressed genes with pathway and network
analyses. Combining gene expression profiles with path-
way and network analyses has helped the identification of
Figure 1 MDS plot for RNA-seq gene expression of KIRC tissue
and normal tissue samples. Tumour refers to tumour tissue
samples from KIRC patients. Normal refers to the matched normal
tissue samples from the same patient. There are totally 68 tumour
and 68 paired normal tissue samples in the MDS plot.
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regulators for downstream genes, regardless that the
expression levels were significantly altered or not.
Construction of a classifier for KIRC prediction
We built a predictive classifier using Support Vector
Machine (SVM) algorithm to classify unknown tissue
samples. The expression levels of differential genes were
utilized as input features. To achieve robust perfor-
mance, we have used boosting with bootstrapping and
aggregation algorithm and randomly selected 4/5 of
samples for training, while the remaining 1/5 of samples
were used for testing. We repeated the process for 50
times. Sensitivity and specificity were used to assess the
classifier performance. As there is always a trade-off
between specificity and sensitivity, we used Receiver
Figure 2 Hierarchical clustering of 136 KIRC and normal tissue samples based on the expression level of the differential genes. The
figure shows hierarchical clusters of tumour and normal tissues using expression levels of 186 differential genes. In the column sidebar of the
figure, pink represents KIRC tissue samples and cyan represents normal tissue samples. In the heatmap, green represents genes that are down-
regulated whereas red represents genes that are down-regulated.
Table 1 Biological functions associated with distinct
differential gene groups
Gene Group GO term (P < 0.01, Fisher’s Exact Test with
Benjamini multiple test correction)
Over-expressed Defence response
Response to environmental stimulus
Under-expressed Organismal physiological process
System development
Organ development
Weakly over-
expressed
Cell-cell signalling
Lip metabolism
Signal transmission across a synapse
Organismal physiological process
Weakly under-
expressed
Excretion
Secretion
Transmembrane transported activity
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Figure 3 Clustering of 537 KIRC and normal tissue samples based on the expression level of the differential genes. The figure shows
hierarchical clusters of all samples including matched and unmatched samples. The KIRC tumour samples were seperated well from normal
samples by using expression levels of differential genes revealed in matched samples.
Figure 4 The taurine and hypotaurine metabolism pathway. This KEGG pathway is enriched for differential genes, colored with yellow, in KIRC.
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Operating Characteristic (ROC) curve to measure the
overall performance of the classifier. If the area under
ROC curve is 1.0 or 100%, it means the classifier is perfect.
The SVM-based classifier achieved average sensitivity, spe-
cificity and area under ROC curve from 50 trials as 96.5%,
97.0% and 98.7% respectively. The performances of the
classifier were summarized in Table 3. The results demon-
strated that the classifier has achieved accurate and robust
classification performance with low standard deviations.
The intelligent machine can be used successfully for cate-
gorizing disease samples with high accuracy.
Discussion
For identification of differentially expressed genes, we
used 68 paired tumour and normal kidney tissue sam-
ples. In each paired samples, one sample was from
KIRC tumour tissue and the paired sample was from
the pathologically normal kidney tissue from the same
patient. Using paired sequencing data obtained from the
same patient can reduce false positives due to genetic
difference or other confounding factors that are not
necessarily related to the cancer. This is particularly
advantageous in avoiding genetically natural polymorph-
isms among the population. Although only the matched
sets of samples were used in the identification of differ-
entially expressed genes, we have obtained highly homo-
genous clusters using expression levels of differentially
Figure 5 The PPAR signalling pathway. This KEGG pathway is enriched for differential genes, colored with yellow, in KIRC.
Table 2 KEGG pathways that are significantly enriched
for differential genes
P-value
(hypergeometric
test)
Pathway
0.002 Taurine and hypotaurine metabolism
0.016 Neuroactive ligand-receptor interaction
0.025 Glycosaminoglycan biosynthesis - heparin
sulfate
0.033 Peroxisome proliferator-activated receptor
(PPAR) signalling pathway
0.0346 Hepatitis C
0.039 Gastric acid secretion
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expressed genes in clustering all samples including 469
unmatched KIRC and 4 normal kidney tissue samples.
Moreover, the SVM-based classifier utilizing the expres-
sion levels of differentially expressed genes was shown
capable of predicting unknown tissue samples with high
accuracy, suggesting that the differentially expressed
genes can serve as expression signatures of the disease.
Analyses of gene expression profiles and differently
Figure 6 Network of molecular transport, heredirary disorder, metabolic disease. In the figure, over-expressed genes were marked in red and
under-expressed genes were marked in green. The node(s) circled with yellow represent gene(s) that can be used as biomarker for the disease.
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expressed genes suggested four different subtypes of the
cancer. This was further supported by the pathway and
network analyses that have revealed differentially disturbed
pathways and networks influenced by the subtypes of the
disease. Analyses of cancer related pathways and networks
not only confirmed some of discoveries that have been
already reported in literature, but also provided new find-
ings. Amongst the significant networks that we identified,
NF-B and UBC are examples of central nodes for
molecular transport, hereditary disorder, metabolic disease
network and network of renal or urological disease. Inter-
estingly, the expression levels of both NF-B and UBC
were not significantly altered in KIRC, instead they highly
interconnect with other genes in the network structure,
suggesting their important regulatory roles in the cancer.
Though they can be considered as markers of the disease,
the differentially expressed gene set shall be further uti-
lized to infer upstream disease causal genes by combining
pathway and network analyses with the systems biology
approaches. This research was part of investigations of
integrative systems biology approaches to identify dis-
rupted pathways in disease development (http://www.
world-academy-of-science.org/worldcomp14/ws/keynotes/
invited_talk_yang). Integrating the disease-associated
Figure 7 Network of renal and urological disease. In the figure, over-expressed genes were marked in red and under-expressed genes were
marked in green. The node(s) circled with yellow represent gene(s)s that can be used as biomarker for the disease.
Table 3 Performance of the classifier
SVM-based Classifier Sensitivity Specificity Area under ROC
Mean 96.5% 97.0% 98.7%
Standard deviation 0.036 0.036 0.015
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networks with differentially expressed genes and pathways
can lead to the identification of useful biomarkers and
effective drug targets.
Conclusions
Our differentially expressed genes and pathway analyses
have utilized large-scale RNA-seq data and have provided
new insights into the molecular mechanisms in the cancer.
In the study, the expression levels of differentially
expressed genes detected in the paired tumour samples
were used as input features for the machine learning clas-
sifier. We were able to identify a set of genes associated
with molecular perturbations in the disease development,
and obtain highly homogenous clusters. The intelligent
machine built for this study was able to achieve high accu-
racy in clustering and classifying the tumour samples.
Indeed, pathway and network analyses based on significant
genes not only confirmed pathways implicated in the dis-
ease, but also identified new roles of unreported pathways
in the cancer. Combing differentially expressed genes with
pathway and network analyses not only provided an
unprecedented opportunity to reveal subtypes of the dis-
ease, but also better understanding of underlying molecu-
lar mechanisms related the cancer development.
Methods
Differentially expressed genes in KIRC
The RNA-seq and meta-data of KIRC were downloaded
from TCGA Data Portal Bulk Download (https://tcga-
data.nci.nih.gov/tcga). The availability of more than 500
cancer patient data has been used advantageously to train
the high performance classifier. Tumour purification and
data quality were investigated. All samples contained at
least 60% tumour nuclei by pathological determination
[7]. Since there are common concerns of sample impurity
in cancer genomics analysis, the next-generation
sequences from this quality of cancerous tissue samples
were considered as sufficient. RNA-seq version 2 data
were provided by University of North Carolina Genome
Centre using the RNA-seq data protocol generated by
the Illumina HiSeq. Normal tissue samples were defined
as pathologically no cancerous nuclei and micronuclei,
and the normal tissue samples contained 4 tissues from
healthy (no cancer) human kidneys, and 68 tissues from
either paired pathologically normal portions of the dis-
ease kidney or paired other side no-cancer healthy kid-
neys from the KIRC patients. The cancerous tissue
samples included 68 matched and 469 unmatched
tumour tissue samples. All cancerous tissue samples con-
tained about 2/3 or more tumorous cell nuclei pathologi-
cally. The edgeR package [8,9] was used for differentially
expressed gene identification. Support Vector Machine
was designed for classifying KIRC samples.
Gene ontology and pathway analyses
We performed Gene Ontology (GO) analysis on differen-
tially expressed genes in KIRC. Fisher exact test with multi-
ple test correction was used to obtain significant GO terms
that are associated with differentially expressed genes. We
also searched for enrichment of differentially expressed
genes in KEGG pathway analysis. Hypergeometric test was
applied to attain significant KEGG pathways. GO and path-
way analyses were conducted using Bioconductor packages
[23]. In addition, Ingenuity Pathway Analysis (http://www.
ingenuity.com) was applied to identify differential networks
in KIRC.
Machine learning classifier
Using expression levels of the differentially expressed
genes, SVM-based classifier was designed to distinguish
cancer from no cancer samples. Different kernels were
tested and linear kernel was adopted in the SVM model.
Boosting with Bootstrapping Aggregation algorithm was
designed. We used five-fold cross-validation to assess
the performance of the classifier. Receiver operating
characteristic (ROC) curves were generated. The perfor-
mance of the machine was evaluated using sensitivity
and specificity defined as:
Sensitivity =
TP
TP + FN
Specificity =
TN
TN + FP
where TP is the count of true positives, here referring to
number of true cancer samples; TN is the count of true
negatives, referring to number of non-cancer (normal tis-
sue) samples; FP is count of the false positives, referring to
non-cancer tissue samples that were misclassified as can-
cer; and FN is the count of false negatives, referring to
cancer tissue samples that were misclassified as normal
(no-cancer) tissue samples. Since there is always a trade-
off between specificity and sensitivity, the area under ROC
curves were used to evaluate the overall performance of
the classifier. A high performance classifier can reach up
to 1.0 (100%) for area under ROC while a random classi-
fier has just about or barely above 0.5 (50%) on the area
under ROC. The SVM-based classifier achieved average
96.5% sensitivity, 97.0% specificity and 98.7% of area under
ROC respectively, thus the classifier can effectively identify
cancer samples.
Additional material
Additional File 1: List of 186 differentially expressed genes and log (FC)
( |log (FC)| > 5).
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